Novacyt (DE:NYZ)
FRANKFURT:NYZ
NYZ Stock Chart & Stats
€0.38
-€0.02(-2.82%)
At close: 4:00 PM EST
€0.38
-€0.02(-2.82%)
Day’s Range― - ―
52-Week Range€0.29 - €0.97
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€30.63M
Enterprise Value€28.35M
Total Cash (Recent Filing)€19.14M
Total Debt (Recent Filing)€10.44M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding72,588,090
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.03
Price to Sales (P/S)1.18
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.58M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins (63% group; >80% for key Primer Design assays) create durable profit leverage as volumes scale. Margins on consumables and reagents support recurring cash conversion and allow operating expense absorption, improving long-term path to EBITDA profitability.
Clinical Franchise & Diversified RevenueA large, growing clinical business (NIPT and related assays) provides recurring, stickier revenue and geographic diversification. Contract wins and Asia‑Pacific growth reduce single‑market exposure and underpin repeat reagent/consumable demand, supporting sustainable top‑line durability.
Regulatory Barrier — IVDR ApprovalsIVDR certification raises technical and regulatory barriers, limiting competitor entry and protecting market share for certified assays. This structural regulatory moat can sustain pricing and adoption over 12–24 months, supporting long‑term commercial stability for certified products.
Bears Say
Structural LossesPersistent operating and net losses across multiple years indicate the current revenue base is insufficient to cover the cost structure. Continued unprofitability increases dependence on external funding, limits retained capital for reinvestment, and heightens execution risk over the medium term.
Cash Burn & Liquidity RiskRapid cash depletion and ~£825k monthly burn create a narrow runway that depends on hitting growth and cost targets. Liquidity pressure raises refinancing and dilution risk, constraining strategic options and increasing the probability that operational missteps force emergency capital raises within 6–12 months.
Material Impairments & Exceptional ChargesLarge non‑cash impairments signal past overpayment or weaker-than-expected integration outcomes, eroding equity and highlighting execution risk in acquisitions. Exceptional charges reduce balance sheet cushions and may limit future M&A appetite or increase scrutiny from lenders and investors.
Novacyt News
NYZ FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €0.97 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €30.63M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 100 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -€0.269 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.269.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.269 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.819%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in DE:NYZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
NYZ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all DE:NYZ earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―
Options Prices
Currently, No data available
---